.svg){kind=small}
Founders raising seed capital have increasingly reached for the Simple Agreement for Future Equity (SAFE). Introduced by Y Combinator in 2013, the SAFE was designed to solve a practical problem: how can founders raise early capital without engaging in lengthy negotiations over valuation, investor rights, liquidation preferences, or governance structures?
The answer was elegant. An investor provides capital today in exchange for the right to receive equity at a later date, usually when the company raises a priced financing round. Its promise was attractive because no interest, no maturity date, no immediate valuation negotiation just a promise of future equity once a priced round arrives.
In the United States, the SAFE quickly became the default instrument for seed-stage fundraising. In India, however, the same simplicity proved difficult to replicate. This obstacle was not commercial practicality but regulatory architecture. Indian company law, securities regulation, and foreign exchange controls are built around clearly recognised categories of financial instruments. A contractual promise of future equity does not fit comfortably within that framework.
The result was the emergence of the iSAFE (India Simple Agreement for Future Equity), introduced by early-stage investment firm 100X.VC in 2019. Understanding why iSAFE looks nothing like its American namesake despite sharing its name is essential for founders, in-house counsel, and investors structuring early-stage rounds in India.
The original YC SAFE is intentionally straightforward. Rather than issuing shares or debt instruments at the time funds are invested, a company enters into a contract under which the investor acquires a future right to receive equity upon the occurrence of specified trigger events.
These trigger events commonly include:
The principal commercial protections negotiated between founders and investors are usually limited to:
Importantly, the SAFE is not required to fit within a predetermined statutory category of security at the time of issuance. It operates as a contractual arrangement whose economic outcome is deferred until a subsequent financing event occurs.
This flexibility is one of the principal reasons for its success in the United States.
The very feature that makes a SAFE attractive, namely its existence outside conventional categories of debt and equity, creates difficulties within the Indian regulatory framework. The SAFE cannot be implemented in India in its original form for several reasons:
Recognising these constraints, 100X.VC introduced the iSAFE in 2019. The innovation was not the creation of a new legal instrument. Rather, it was the adaptation of SAFE economics into a regulatory form already recognised under Indian law.
An iSAFE is typically structured through the issuance of Compulsorily Convertible Preference Shares (CCPS).
Under this model:
The economic outcome resembles a SAFE. The legal structure does not. This distinction is crucial. The iSAFE functions because it is built upon an established statutory foundation rather than an unclassified contractual promise.
As the CCPS is a category the Companies Act, 2013 already recognises, an iSAFE issuance can be executed under Sections 42 (private placement), 55 (issue and redemption of preference shares), and 62 (further issue of share capital), read with the Companies (Share Capital and Debentures) Rules, 2014 and the Companies (Prospectus and Allotment of Securities) Rules, 2014.
An iSAFE is not, strictly speaking, a SAFE at all. It is a preference share subscription agreement engineered to replicate SAFE-like commercial terms speed, minimal negotiation, deferred valuation while staying inside a statutorily defined instrument.
The issuance of iSAFE instruments is generally supported by existing provisions of the Companies Act, 2013, including:
The relevant procedural requirements are supplemented by:
Because CCPS are recognised securities, regulatory uncertainty surrounding allotment and classification is substantially reduced. However, this structure comes with important consequences.
Where the investor is non-resident, the iSAFE remains subject to FEMA pricing and reporting norms; because CCPS are a recognised capital instrument under the FEMA (Non-Debt Instruments) Rules, 2019, this compliance path is more predictable than for a plain contractual SAFE.
One practical consequence follows directly from this structure: because iSAFE issuances are share allotments, they are only available to companies not to LLPs or partnership firms, which cannot issue preference shares at all.
Like a traditional SAFE, an iSAFE seeks to postpone detailed valuation negotiations until a later financing round. The conversion economics usually take one of three forms:
The Importance of MFN Clauses
A recurring feature of iSAFE documentation is the Most Favoured Nation (MFN) provision. An MFN clause generally permits an investor to elect more favourable terms subsequently granted to other convertible investors.
While commercially understandable, founders should approach these provisions with caution. In bridge rounds involving multiple iSAFE issuances, a low valuation cap agreed with one investor may effectively cascade across the entire investor base through MFN elections, significantly affecting dilution outcomes.
Conversion ordinarily occurs on:
Unlike a purely contractual SAFE, however, the iSAFE inherits statutory limitations applicable to preference shares.
Under the Companies Act, 2013, preference shares generally cannot have a tenure exceeding twenty years, subject to limited exceptions.
Although seed-stage instruments ordinarily convert well before this threshold becomes relevant, the statutory ceiling highlights an important conceptual difference between a contractual promise and a recognised security.
Another distinction concerns financial reporting. A SAFE in the United States is frequently perceived as sitting outside traditional debt accounting treatment until conversion.
The iSAFE produces a different outcome. Because the instrument is structured as CCPS, the investment ordinarily forms part of the company's capital structure and is reflected within shareholders' funds rather than appearing as a conventional liability.
Founders should appreciate the impact this may have on cap table presentation, investor reporting, and future fundraising discussions.
The journey from SAFE to iSAFE illustrates a broader lesson about legal transplantation. Financing instruments do not travel across jurisdictions unchanged. Their success depends on compatibility with the local regulatory ecosystem.
The American SAFE derives its strength from contractual flexibility and regulatory minimalism. Indian law, by contrast, requires financing instruments to operate within well-defined statutory categories. The iSAFE therefore accomplishes the same commercial objective through a fundamentally different legal route by embedding SAFE economics within compulsorily convertible preference shares.
For founders and investors, the key takeaway is straightforward: the SAFE and the iSAFE may share a name and a commercial purpose, but they are not the same instrument. Treating them as interchangeable can create significant legal, regulatory, and compliance risks. Understanding the distinction at the outset is far less expensive than discovering it during the next financing round.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
